Last reviewed · How we verify
NCT00006981
Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days
Phase 1 trial testing SS1(dsFv)-PE38 immunotoxin in Cervical Cancer. Completed.
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 December 2000 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SS1(dsFv)-PE38 immunotoxin — full drug profile →
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
- Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
National Cancer Institute (NCI)
Who can join
18 and older, any sex, with Cervical Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer. PURPOSE: Phase I trial to study the effectiveness of immunotoxins in treating patients who have advanced cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
Morello A, Sadelain M, Adusumilli PS. · · 2016 · cited 402× · PMID 26503962 · DOI 10.1158/2159-8290.cd-15-0583 -
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ, Wang MF, Chen HL, Shang D, et al · · 2020 · cited 179× · PMID 32061257 · DOI 10.1186/s12943-020-01151-3 -
Mesothelin as a biomarker for targeted therapy.
Lv J, Li P, Li P. · · 2019 · cited 101× · PMID 31463062 · DOI 10.1186/s40364-019-0169-8 -
Emerging trends in the immunotherapy of pancreatic cancer.
Banerjee K, Kumar S, Ross KA, Gautam S, et al · · 2018 · cited 78× · PMID 29242097 · DOI 10.1016/j.canlet.2017.12.012 -
Immunogenicity of Immunotoxins Containing <i>Pseudomonas</i> Exotoxin A: Causes, Consequences, and Mitigation.
Mazor R, Pastan I. · · 2020 · cited 67× · PMID 32695104 · DOI 10.3389/fimmu.2020.01261 -
<i>Pseudomonas</i> Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin.
Havaei SM, Aucoin MG, Jahanian-Najafabadi A. · · 2021 · cited 49× · PMID 34976821 · DOI 10.3389/fonc.2021.781800 -
Engineered antibody fusion proteins for targeted disease therapy.
Silver AB, Leonard EK, Gould JR, Spangler JB. · · 2021 · cited 40× · PMID 34706833 · DOI 10.1016/j.tips.2021.09.009 -
Amatuximab and novel agents targeting mesothelin for solid tumors.
Baldo P, Cecco S. · · 2017 · cited 30× · PMID 29184420 · DOI 10.2147/ott.s145105
Verify or expand the search:
- PubMed search for NCT00006981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00006981 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 29 April 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00006981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing